Organization (Industry)
Ivoclar Vivadent (Germany)
ClinicalTrials.gov lists Ivoclar Vivadent (Germany) as lead sponsor of 21 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Ivoclar Vivadent (Germany): 21 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (8)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dental Caries | 10 |
| Mouth, Edentulous | 2 |
| Tooth Wear | 2 |
| Anodontia | 1 |
| Dentin Sensitivity | 1 |
Showing 5 of 8 disease areas.
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 5 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 6 |
| 2017 | 3 |
Showing 10 of 20 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=12) | 50% on time (n=14) |
Journals published in (23)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of dentistry | 4 |
| Clinical oral investigations | 3 |
| Journal of prosthodontic research | 3 |
| Journal of the American Dental Association (1939) | 3 |
| Caries research | 2 |
Showing 5 of 23 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 581 | 137 | 2025-12-30 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 1 |
FDA recalls (4)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Ivoclar Vivadent IPS e.max ZirCAD CER/inLab LT A1 C17/5 -ceramic for dental use, intended for IPS e.max ZirCAD presintered yttrium oxide-stabilized zirconium oxide blocks for the CAD/CAM technology Product Number: 686193 | Class II | 2020-04-13 |
| Ivoclar Vivadent IPS e.max ZirCAD CER/inLab LT A2 C17/5 - ceramic for dental use,intended for IPS e.max ZirCAD presintered yttrium oxide-stabilized zirconium oxide blocks for the CAD/ CAM technology Product Number: 686194 | Class II | 2020-04-13 |
| Ivoclar Vivadent IPS e.max ZirCAD CER/inLab LT A3 C17/5 - ceramic for dental use, intended for IPS e.max ZirCAD presintered yttrium oxide-stabilized zirconium oxide blocks for the CAD/ CAM technology Product Number: 686195 | Class II | 2020-04-13 |
| Ivoclar Vivadent IPS e.max ZirCAD CER/inLab Start.Kit LT - ceramic for dental use, intended for IPS e.max ZirCAD presintered yttrium oxide-stabilized zirconium oxide blocks for the CAD/ CAM technology Product Number: 686282EN | Class II | 2020-04-13 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 21 | 2026-07-15 |
Manufacturing and distribution sites (4)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| IVOCLAR VIVADENT AG | SCHAAN, LI | FDA | |
| IVOCLAR VIVADENT, INC. | AMHERST, US | FDA | Ivoclar Vivadent, Inc. |
| Ivoclar Vivadent GmbH | Ellwangen Baden-Wurttemberg, DE | FDA | Ivoclar Vivadent (Germany) |
| IVOCLAR VIVADENT, INC. | Lipa City Batangas, PH | FDA | Ivoclar Vivadent, Inc. |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| University of Michigan | Co sponsors trial with | 1 |
Latest dated events (664)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-15 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-07-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 664 events.
Biomarker capability evidence (8)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| OTOR | Trial collaborator | Named in trial inclusion criteria |
| PSEN1 | Trial collaborator | Named in trial inclusion criteria |
| PSEN2 | Trial collaborator | Named in trial inclusion criteria |
| TFF1 | Trial collaborator | Named in trial inclusion criteria |
| OTOR | Trial collaborator | Mentioned in trial text |
Showing 5 of 8 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.